Clinical Trial Update: Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) [Phase 2]

View source ↗

Summary

Phase 2 study of the AKT inhibitor MK-2206 in patients with metastatic pancreatic neuroendocrine tumors; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: PANCREAS, Neuroendocrine | Phase 2 | Status: COMPLETED | Results posted: 2016-02-18